Language
English
Publication Date
3-17-2026
Journal
The Journal of Infectious Diseases
DOI
10.1093/infdis/jiaf572
PMID
41287255
PMCID
PMC13017828
PubMedCentral® Posted Date
11-25-2025
PubMedCentral® Full Text Version
Post-print
Abstract
Traditional vaccine clinical trials sample blood from all participants. In contrast, the test-negative immune correlates (TNIC) design only samples blood from participants who develop symptoms. We compared traditional to test-negative immune correlates methods in the mRNA-1273 severe acute respiratory syndrome coronavirus 2 vaccine efficacy clinical trial. Using a neutralizing antibody assay, hazard ratios were 0.48 (95% confidence interval [CI], .29-.73) and 0.55 (95% CI, .28-1.06) for traditional and test-negative methods, respectively. Analogous ratios for binding antibody assay were 0.69 (95% CI, .52-.94) and 0.78 (95% CI, .50-1.20). The results support use of the logistically simpler TNIC design.
Keywords
Humans, COVID-19, Antibodies, Neutralizing, SARS-CoV-2, Antibodies, Viral, COVID-19 Vaccines, Male, Research Design, Female, correlates of risk, correlates of protection, test-negative design, vaccines
Published Open-Access
yes
Recommended Citation
Follmann, Dean; Dang, Lauren; Chu, Eric; et al., "A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure-Proximal Design but Requires Far Fewer Blood Samples" (2026). Faculty, Staff and Students Publications. 8817.
https://digitalcommons.library.tmc.edu/baylor_docs/8817